Company Overview of Abbott Healthcare Pvt. Ltd.

Company Overview
Abbott Healthcare Pvt. Ltd., a health care company, provides nutritional products, laboratory diagnostics, medical devices, and pharmaceutical therapies. The company develops products in areas, such as antibiotic, respiratory, gastro, dermat, nutritional, parenteral, anti parasitic, gyne, opthalmology/otolaryngology, anti cancer, cardiac, anti diabetic, psychiatry, NSAIDS/pain, hormonal, anti parasitic, and stomatologicals. It produces a range of formulations and dosage forms, such as tablets, which include uncoated, and coated (film and sugar coated); hard gelatin capsules filled with granules, powders, pellets, and tablets; soft gelatin capsules; liquid orals, syrups, and suspensions; topicals, which include lotions and emulsions; and injectables (large volume parenterals). The company was incorporated in 1997 and is based in Mumbai, India. Abbott Healthcare Pvt. Ltd. operates as a subsidiary of Abbott Laboratories.

http://www.abbott.co.in/about-us-comapny-history.html

Founded in 1888, by a young Chicago based physician, Dr. Wallace Calvin Abbott, the organization has been devoted to discovering new medicines, new technologies and new ways to manage health

Today, Abbott is a worldwide broad based healthcare company whose products and technologies span the continuum of care - from diagnostics to devices, from nutrition to pharmaceutical therapies. Our comprehensive line of products encircles life itself - addressing important health needs from infancy to the golden years.Abbott is known for its innovative products and a commitment to applying leading edge science and technologies to advance patient care. Our product and services are designed to maintain our reputation for high quality and optimal performance Abbott has sales, manufacturing, research and development, and distribution facilities around the world, close to where our customers need us to be. Fast Facts: Chairman and CEO: Miles D. White Corporate Headquarters: North suburban Chicago, Illinois, USA Number of Employees: Approximately 70,000 worldwide Revenue: INR 121,000 Crores 2012 Income after tax: INR 31,500 Crores Presence: 150+ countries About Abbott India Limited Abbott India Limited is one of India's fastest growing pharmaceutical companies and part of Abbott's Global Pharmaceutical business in India. Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a subsidiary of Abbott Laboratories, enjoys strong brand equity in multiple therapeutic categories such as Women's Health, Gastroenterology, Neurology, Thyroid, Diabetes & Urology, Pain Management, Vitamins, Anti-Infectives & other therapy areas. Abbott India Limited's success is driven by a combination of a highly competent and motivated commercial team, R&D backed products, aided by strong alliances and partnerships. Abbott India Limited employs over 2,600 people and reaches customers through a wide network of 35 distribution points, catering to over 4,500 stockists and 150,000 retail outlets. The company has over 100 employees at a state-of-the-art formulation plant at Verna, Goa. The manufacturing plant is designed to produce high quality, high volume formulations using cost efficient processes and has well equipped laboratories and trained personnel to ensure compliance with international quality standards. The company has in-house development and medical teams to undertake product and clinical development tailored to needs of the Indian market. Abbott India Limited believes in providing quality healthcare through a mix of global and local products which directly affect the life of the common Indian

Piramal | Healthcare
Mr. Ajay G Piramal is the Chairman of the Piramal Group. He is known for identifying opportunities ahead of the curve. In the late 1980s, Mr. Piramal took a decision to move out from the dwindling textiles business to pharmaceuticals. This was at a time when international companies were exiting the Indian pharma markets due to various socio-economic reasons. Mr. Piramal bought Nicholas Labs in 1988 at USD 4 million. We forayed into the healthcare space in 1988 with a move that was contrarian at that time as most pharmaceutical players were exiting India due to the existing business climate. It has been 25 years, and we have established ourselves as one of the most recognisable and respected names in the pharmaceutical industry. Today, we have manufacturing bases across India, UK, Scotland, USA and Canada. Our critical care products are available in the emergency rooms of most hospitals across the globe and our products are available in over 100 countries. We are presently the third largest player in the global Inhalation Anesthesia (IA) market, and the only company in the world with a complete product portfolio of inhalation anesthetics drugs. Our custom manufacturing capabilities make us one of the largest custom manufacturing companies in the world. The UN Conference on Trade and Developments World Investment Report 2011 ranks us among the top 5 in the world. Through the years, we at Piramal | Healthcare have partnered with the largest and most reputed organisations in the global pharmaceutical industry to expand our product offering and deliver the best innovations to our customers. Piramal | Healthcare is made up of the following four key business divisions:

Pharma Solutions Critical Care Consumer Products Diagnostics

Contact Us Piramal | Healthcare Pharma Solutions & Critical Care & Diagnostic Office 247 Business Park, A-Wing, 6th Floor

LBS Marg, Vikhroli (West) Mumbai - 400083. Maharashtra, India Tel: +91-22-30956666 Consumer Products Division 4th Floor, Piramal Annexe Tower Ganpatrao Kadam Marg Lower Parel (W) Mumbai - 400013. Maharashtra, India Tel: + 91-22-32000055

Press Release

Press Release
Abbott Completes Acquisition of Piramal's Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India

Deal propels Abbott to top position in India with pharmaceutical sales expected to exceed $2.5 billion by 2020 9/8/2010

Abbott Park, Illinois (NYSE: ABT) Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging markets. Throughout the past decade, Abbott has established a leading presence in emerging markets today, more than 20 percent of the company's total sales are generated in these growing economies. "The acquisition of Piramal's Healthcare Solutions business further strengthens Abbott's growing presence in emerging markets," said Miles D. White, chairman and chief executive officer, Abbott. "Piramal's portfolio of well-known, trusted products has served patients in India for decades. Combined with existing product offerings, Abbott is uniquely positioned to meet the needs of one of the world's fastest-growing pharmaceutical markets." India's rapid pharmaceutical market growth is being driven largely by branded generics. The market will generate nearly $8 billion in pharmaceutical sales this year, a number that is expected to more than double by 2015. Abbott expects its pharmaceutical sales in India to exceed $2.5 billion by 2020. Piramal's Healthcare Solutions business has a comprehensive portfolio of branded generics, including market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience. The Healthcare Solutions business will operate as a separate business unit, reporting into Abbott's newly-created Established Products Division (EPD), which was formed to focus on branded generics, maximizing the opportunity in emerging markets. The business will continue to be led by its current India-based management team. "Piramal's proven business model in India and experienced local leadership team, combined with the global resources of Abbott, will allow us to build upon Piramal's commitment to quality and service," said Michael J. Warmuth, senior vice president, Established Products, Pharmaceutical Products Group, Abbott. Abbott now employs approximately 10,000 people across all of its businesses in India. Abbott, through a wholly-owned subsidiary, purchased the assets of Piramal's Healthcare Solutions business for a $2.2 billion up-front payment with additional payments of $400 million annually for the next four years, beginning in 2011. This transaction will not impact Abbott's ongoing earnings per share guidance in 2010. About Abbott Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott Forward-Looking Statement Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and in Item 1A, "Risk Factors," to our Quarterly Report on Securities and Exchange Commission Form 10-Q for the period ended March 31, 2010, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

Abbott acquires Piramal's healthcare unit

ET Bureau & Agencies May 21, 2010, 11.48am IST

Tags:

Piramal Healthcare| Pharma| M&A| Abbott

(Gainers & losers Top 5 picks Mid-term picks Live Stock tips MF NFO)

MUMBAI: Shares of Piramal Healthcare and Abott India reacted sharply on Friday after Abbott acquired Piramal Healthcare's domestic fomulation business. ( Watch ) Abbott will make an upfront payment of $2.12 billion and annual payments of $400 million per year for next 4 years. With this acquisition, Abbott says, it will become the largest pharmaceuticals company in India.

abbott, acquisition, Business and Markets, genetic, healthcare, India, Indian companies, Merger, Pharma Industry, Piramal

Abbott Laboratories Buys Piramal Healthcare Limited Biz for $3.72B

May 24, 2010 jkwaran Leave a comment

Abbott May 21 announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramals Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbotts emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbotts collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio. This strategic action will advance Abbott into the leading market position in India, one of the worlds most attractive and rapidly growing markets, said Miles D. White, chairman and chief executive officer, Abbott. Our strong position in branded generics and growing presence in emerging markets is part of our ongoing diversified pharmaceutical strategy, complementing our market-leading proprietary pharmaceutical offerings and pipeline in developed markets. Emerging markets represent one of the greatest opportunities in health care not only in pharmaceuticals but across all of our business segments. Today, emerging markets represent more than 20 percent of Abbotts total business, said Mr. White. With this deal, the combined Healthcare Solutions and Abbott businesses will become the clear market leader in India, with a market share of approximately 7 percent, said Ajay Piramal, chairman, Piramal Group. This was our collective vision and I am glad that those who are part of Piramals Healthcare Solutions business will realize this dream.

The Indian Pharmaceutical Market India is one of the worlds fastest-growing pharmaceutical markets, due in large part to branded generics. The market will generate nearly $8 billion in pharmaceutical annual sales this year, a number that is expected to more than double by 2015. Abbott estimates the growth of its Indian pharmaceutical business with Piramal to approach 20 percent annually, with expected sales of more than $2.5 billion by 2020. Branded generics have significant brand equity in many international markets, providing durable, sustainable franchises for future growth. Piramal markets the products in its Healthcare Solutions business in India only and does not market traditional generic products. Today, branded generics account for 25 percent of the global pharmaceutical market, have the majority of market share in the largest emerging markets, and are expected to outpace growth of patented and generic products. The Mumbai-based Piramal Healthcare Solutions business has a comprehensive portfolio of branded generics with annual sales expected to exceed $500 million next year in India, and market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience. This business grew 23 percent in 2010 (fiscal year ended March 31, 2010), faster than the market in India. Piramal has a strong commercial presence, including the largest sales force in India with a unique model that includes dedicated sales personnel in rural areas inhabited by 70 percent of the population. The combined Abbott and Piramal sales forces will be the industrys largest in India. Piramals Healthcare Solutions business will become part of Abbotts newly created, stand-alone Established Products Division. Piramals Healthcare Solutions business employs more than 5,000 people in India. Abbott, which is celebrating its 100th year in India, has more than 2,500 employees across all of its businesses there. Abbotts Established Products Strategy Throughout the past decade, Abbott has built a leading portfolio of branded generics, through its own products as well as those acquired with the 2001 acquisition of Knolls pharmaceutical business. In 2007, the company established a separate business unit within its international pharmaceutical division dedicated to established products. Additionally, a new geographic region focused on Russia, India and China was created, which resulted in the doubling of Abbotts growth rate in those countries. Most recently, the company acquired Solvay Pharmaceuticals, obtaining a diverse branded generics portfolio and providing significant critical mass in key emerging markets. As a result of these combined actions, Abbott is now among the leading multinational health care companies in numerous emerging markets. Approximately 20 percent of Abbotts pharmaceutical sales today are in emerging markets.

We have assembled a market-leading branded generics portfolio tailored to the unique needs of emerging markets, strongly positioning Abbott to meet the current and future geographic and market dynamics in pharmaceuticals, said Olivier Bohuon, executive vice president, global pharmaceuticals, Abbott. Piramal has built a reputation for high-quality, well-known and trusted pharmaceutical brands. We look forward to welcoming the accomplished staff of Piramals Healthcare Solutions business to Abbott. Pharmaceutical sales in emerging markets are expected to grow at three times the rate of developed markets and account for 70 percent of pharmaceutical growth over the next several years. This explosive growth is occurring as demographics, rising incomes, modernization of health systems and an increase in the treatment of chronic disease create greater demand for medicines. Financial Highlights Under terms of the agreement, Abbott will purchase the assets of Piramals Healthcare Solutions business for a $2.12 billion up-front payment with payments of $400 million annually for the next four years, beginning in 2011. The transaction will not impact Abbotts ongoing earnings per share guidance in 2010. Abbott plans to fund the transaction with cash on the balance sheet. This transaction is subject to shareholder approval of Piramal Healthcare Limited and other customary closing conditions, and is expected to close in the second half of 2010. This transaction is being conducted by a wholly-owned subsidiary of Abbott, resulting in full ownership of the assets of Piramals Healthcare Solutions business (Domestic Formulations). Abbott Conference Call Abbott will conduct a special conference call today at 7:30 a.m. Central time (8:30 a.m. Eastern time) to provide an overview of the transaction. The live Web cast will be accessible through Abbotts Investor Relations Web site at www.abbottinvestor.com. For more information on todays announcement, please go to Abbotts press kit at www.abbott.com/PHSMediaKit.